Teva Pharmaceutical Industries (NYSE:TEVA) has seen its stock move steadily over the past month, gaining about 5%. Investors ...

We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra Investments’s Substack by Kontra. In this ...

Jefferies London Healthcare Conference Tuesday, November 18, 2025, at 11:00 A.M. Greenwich Mean Time (6:00 A.M. ET) To access a live webcast of the presentation, visit Teva’s Investor Relations ...

Harel Insurance Investments & Financial Services Ltd. increased its Teva holding to 6.84% of its reportable U.S. equity ...

Explore how Teva Pharmaceutical (NYSE:TEVA) strengthens its global presence and influence in Healthcare Stocks worldwide.

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their ...

A Relative Strength Rating upgrade for Teva Pharmaceutical ADR shows improving technical performance. Will it continue?

The last remaining defendants in New York’s once-sprawling opioid trial settled on Thursday. By Sarah Maslin Nir The agency cited Teva’s continuing supply problems as well as those of other drug ...

Teva Pharmaceutical Industries Ltd. will pay $35 million to settle claims it delayed generic competition in the asthma inhaler market.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Thursday. A number of ...